KRAS and neoplasm: BBO-8520 exerted more potent and sustained inhibition of KRAS <sup>G12C</sup> and anti-tumor activity <i>in vitro</i> and <i>in vivo</i> compared with sotorasib, a KRAS <sup>G12C</sup> (OFF)-only inhibitor.